Log In Sign up
The largest database of trusted experimental protocols

Anti cd4 clone gk1

Manufactured by BioXCell
Visit Supplier
Sourced in United States

Anti-CD4 (clone GK1.5) is a monoclonal antibody that specifically binds to the CD4 cell surface receptor. It is a commonly used tool in immunological research and analysis.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd8 clone 2, by BioXCell (32 mentions) Anti nk1.1 clone pk136, by BioXCell (13 mentions) Anti cd8α clone 2, by BioXCell (7 mentions) Anti cd8 clone yts169.4, by BioXCell (7 mentions) Rat igg2b clone ltf 2, by BioXCell (6 mentions) Anti cd8 clone 53, by BioXCell (6 mentions) Anti ifn γ clone r4 6a2, by BioXCell (4 mentions) Anti cd8a clone 2, by BioXCell (4 mentions) Anti cd8β clone lyt 3, by BioXCell (4 mentions) Rat igg2a clone 2a3, by BioXCell (4 mentions) Clone ltf 2, by BioXCell (4 mentions) Rat igg2b isotype control clone ltf 2, by BioXCell (4 mentions) Anti pd l1 ab clone 10 f 9g2, by BioXCell (3 mentions) Anti il 12p40 clone c17, by BioXCell (3 mentions) Anti pd 1 clone rmp1 14, by BioXCell (3 mentions) Diphtheria toxin, by Merck Group (3 mentions) Isotype control antibody clone ltf 2, by BioXCell (2 mentions) Anti cd8β clone 53 5.8, by BioXCell (2 mentions) Anti cd8 depleting antibody clone 2, by BioXCell (2 mentions) Mfcd00163490, by Merck Group (2 mentions)

Spelling variants of this product

Anti-CD4 (GK1.5, (39 citations) Anti-CD4 (32 citations) Clone GK1.5 (27 citations) Anti-CD4 antibody (clone GK1.5, (20 citations) CD4 (clone GK1.5, (8 citations) Anti-CD4 mAb (clone GK1.5, (7 citations) Rat anti-CD4 (clone GK1.5, (5 citations) Anti-CD4 (rat IgG2b clone GK1.5, (4 citations) Rat anti-mouse CD4 (clone GK1.5) (3 citations) Anti-mouse CD4 mAb (clone GK1.5; (2 citations)

90 protocols using anti cd4 clone gk1

1

Immune Cell Depletion in MC38 Tumor

Check if the same lab product or an alternative is used in the 5 most similar protocols
To deplete immune cells from MC38 tumor–bearing mice, 100 μg of anti-CD4 (clone GK1.5, catalog BP0003-1, BioXcell), 100 μg of anti-CD8 (clone 2.43, catalog BP0061, BioXcell), or 100 μg of anti-NK1.1 (clone PK136, catalog BP0036, BioXcell) depletion antibodies were administered i.p. starting on days 7, 8, and 9 after tumor implantation and then once per week for the duration of the experiment. Intraperitoneal injections of bintrafusp alfa (492 μg) and NC410 (250 μg) were given i.p. on days 8, 10, and 13. Spleens were obtained from animals upon termination of the experiment to determine immune cell population depletion efficiency by flow cytometry (Supplemental Figure 4).
Horn L.A., Chariou P.L., Gameiro S.R., Qin H., Iida M., Fousek K., Meyer T.J., Cam M., Flies D., Langermann S., Schlom J, & Palena C. (2022). Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication. The Journal of Clinical Investigation, 132(8), e155148.
+ Open protocol
+ Expand
2

Immune Cell Depletion in Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were administered depleting antibodies or appropriate isotype control antibodies intraperitoneally (IP) for each experiment as follows: CD8 Depletion: 250 μg of anti-CD8a clone 2.43 (BioXCell, Lebanon, NH), starting day 6 and weekly thereafter. CD4 Depletion: 250 μg of anti-CD4 clone GK1.5 (BioXCell), starting day 6 then weekly thereafter. BALB/c NK cell depletion: 20 μL of anti-asialo GM1 rabbit serum (Wako Chemicals, Richmond, VA) or control rabbit serum, starting day 6, repeated every 4 days for a total of 4 injections. BL/6 NK cell depletion: 200 μg of anti-NK1.1 clone PK-136 (BioXCell) starting day 6, repeated every 4 days for a total of 4 injections. IFN-γ depletion: 100 μg of anti-IFN- γ clone R4–6A2 (BioXCell), on days 7, 9, 15 and 21. After repeated antibody injections, some mice developed a fatal anaphylactic reaction, which correlated with tumor burden. These mice were censored from survival curves since they did not meet the experimental endpoint, and antibody treatments were discontinued for the remaining mice. When more than half of the mice in a treatment group died or were sacrificed, the group was censored from the tumor regression curves to avoid skewing the mean.
Mastria E.M., Cai L.Y., Kan M.J., Li X., Schaal J.L., Fiering S., Gunn M.D., Dewhirst M.W., Nair S.K, & Chilkoti A. (2017). Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity. Journal of controlled release : official journal of the Controlled Release Society, 269, 364-373.
+ Open protocol
+ Expand
3

Radiation-Induced Immune Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
For PD-L1 blockade, anti-PD-L1 Ab (clone 10 F.9G2, BioXcell), or rat IgG2b (clone LTF-2, BioXcell) were given intraperitoneally (i.p.) every third day from the day RT performed at a dose of 200 μg/mouse. For in vivo depletion of lymphocytes, 200 μg of anti-CD4 (clone GK1.5, BioXcell), anti-CD8β (clone Lyt 3.2, BioXcell), anti-NK1.1 (clone PK136, BioXcell) Abs, or rat IgG2b (clone LTF-2, BioXcell) Ab were injected i.p. every third day for three times from the day when RT was given. For in vivo depletion of IL-12 and IFN-γ, 1 mg of anti-IL-12p40 (clone C17.8, BioXcell) and anti-IFN-γ (clone R4−6A2, BioXcell) Abs were administrated by i.p. injection at the day when RT was performed, with follow-up doses of 500 μg for five consecutive days.
Oba T., Long M.D., Keler T., Marsh H.C., Minderman H., Abrams S.I., Liu S, & Ito F. (2020). Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nature Communications, 11, 5415.
+ Open protocol
+ Expand
4

Leukemia Xenograft Mouse Model

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
The luciferase expressing, BCR-ABL1+Arf−/− B-cell acute lymphoblastic leukemia line was originally provided by Dr. Richard Williams (20 (link)–23 ). Leukemia cells were transduced with lentiviruses expressing non-silencing control shRNA (shNS) or shRNA against Ppp3r1, which encodes the essential regulatory subunit of calcineurin (shCnB), with over 90% knockdown as previously described (14 (link)). A total of 5×105 cells were transferred via tail vein injection into un-irradiated, 6–8 week-old, female wild type (WT) or immune compromised recipients. After intraperitoneal injection of luciferin and anesthesia with inhaled isoflurane, leukemia burden was measured by the In Vivo Imaging System (IVIS) manufactured by Perkin Elmer (Waltham, MA). Mice were removed from the study and euthanized when ill-appearing or the luciferase signal exceeded 108 photons/second, whichever came first. Cyclosporine was administered via oral gavage at 25mg/kg/dose daily, as previously described (13 (link)). Anti-CD8 (clone 2.43) and anti-CD4 (clone GK1.5) were purchased from Bio X Cell (West Lebanon, NH). Recombinant murine IL-12-p70 was purchased from Peprotech (Rocky Hill, NJ).
Rabe J.L., Gardner L., Hunter R., Fonseca J.A., Dougan J., Gearheart C.M., Leibowitz M.S., Lee-Miller C., Baturin D., Fosmire S.P., Zelasko S.E., Jones C.L., Slansky J.E., Rupji M., Dwivedi B., Henry C.J, & Porter C.C. (2019). IL-12 abrogates calcineurin-dependent immune evasion during leukemia progression. Cancer research, 79(14), 3702-3713.
+ Open protocol
+ Expand
5

Flow Cytometry Analysis of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following fluorochrome-conjugated antibodies were used for flow cytometry: anti-mouse CD44-FITC (IM7), CD11C-APC (N418), IFNγ-APC (XMG1.2), B220-PE (RA3-6B2), CD19-FITC (1D3), CD62L-PE (MEL-14), CD8-PE (53–6.7), CD40L-PE (MR1), TNFα-PE (MP6-XT22), CD4-APC/Cy7 (RM4-5) and control IgG mAbs were purchased from Biolegend. Ki67-FITC staining set was purchased from BD. Foxp3-APC staining kit was purchased from eBiosciences. Cell Proliferation Dye eFluor™ 450 were purchased from Invitrogen. Cyclophosphamide (CTX) was from MP Biomedicals and was intraperitoneally injected to mice at 150 mg/kg. Retronectin was from Takara and was used for coating of non-treated plates (Corning) at 12 μg/ml. For T cell depletion, anti-CD4 (clone GK1.5) and anti-CD8 (clone 2.43) antibodies, both from BioXCell, were injected i.p. at 100 μg each per mouse 2 days before CTX and were administered once a week thereafter for a total of 4 injections.
Kuczma M.P., Ding Z.C., Li T., Habtetsion T., Chen T., Hao Z., Bryan L., Singh N., Kochenderfer J.N, & Zhou G. (2017). The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells. Oncotarget, 8(67), 111931-111942.
+ Open protocol
+ Expand
6

Antibody-Mediated T Cell Depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols
MCA38 and CT26 colon tumors grew to around 4-5 mm in diameter (Day 0). Mice were randomly assigned to the indicated groups, and received anti-CD4 (clone: GK1.5, Bio X Cell) or anti-CD8 antibody (clone: 53-6.72, Bio X Cell) treatments (200 μg/mouse, i.p. injection) on days 0, 2, and 8. At the end of the experiments, the efficiency of CD4+ and CD8+ T cell depletion was verified by flow cytometry analysis [27 (link)].
Zhang Y., Gao J., He Y., Qi Z., Qian L., Chen W., Xu H., Yue Y., Mao X., Guo S., Zhou Y., Zhou S., Qin S., Zhang X, & Huang Y. (2023). Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy. Journal of Immunology Research, 2023, 5867047.
+ Open protocol
+ Expand
7

T Cell Depletion for Vena Cava Ligation

Check if the same lab product or an alternative is used in the 5 most similar protocols
For T cell depletion experiments, animals were treated with anti-CD4 (clone GK1.5) and anti-CD8 (clone 2.43) monoclonal antibodies (1 mg each) or 2 mg of isotype matched control antibody (clone LTF-2) (Bio X Cell, West Lebanon, NH, USA) via intraperitoneal injections on the days −1, 0, and +7 relative to the vena cava ligation. Depletion of greater than 97% CD4+ and CD8+ T cells was confirmed by flow cytometric analysis of T cell populations in the spleen as described in the flow cytometry section. Thrombi harvested from separate cohorts of age and sex matched animals undergoing the same treatment protocol were used to generate thrombus weight data/histological analyses and molecular studies.
Mukhopadhyay S., Gabre J., Chabasse C., Bromberg J.S., Antalis T.M, & Sarkar R. (2020). Depletion of CD4 and CD8 Positive T Cells Impairs Venous Thrombus Resolution in Mice. International Journal of Molecular Sciences, 21(5), 1650.
+ Open protocol
+ Expand
8

Antibody depletion in pIgR-/- mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isoflurane-anesthetized pIgR−/− mice were injected intraperitoneally with 200 μg of anti-CD8 (clone 2.43, BioXCell; catalog no. BE0061), anti-CD4 (clone GK1.5, BioXCell; catalog no. BE0003–1), or rat IgG2b isotype control (clone LTF-2, BioXCell; catalog no. BE0090) on week 1 followed by weekly injection of 100 μg of each antibody for 3 or 15 weeks as indicated. Antibodies were dissolved in sterile phosphate-buffered saline (PBS) in a total volume of 100 μl for each injection.
Richmond B.W., Mansouri S., Serezani A., Novitskiy S., Blackburn J.B., Du R.H., Fuseini H., Gutor S., Han W., Schaff J., Vasiukov G., Xin M.K., Newcomb D.C., Jin L., Blackwell T.S, & Polosukhin V.V. (2020). Monocyte-derived dendritic cells link localized secretory IgA deficiency to adaptive immune activation in COPD. Mucosal Immunology, 14(2), 431-442.
+ Open protocol
+ Expand
9

T Cell and NK Cell Depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols
To deplete NK cells, CD4+ T cells and CD8+ T cells, tumour-bearing mice were intraperitoneally injected with anti-NK1.1 (clone PK136, BioXCell), anti-CD4 (clone GK1.5, BioXCell), anti-CD8-α (clone 2.43, BioXCell) or isotype control (RatIgG1,BioXcell) antibodies at an initial dose of 400 mg 1 d before treatment, followed by 200 mg every 3 d. Depletion of CD8+ T cells, CD4+ T cells and NK cells was confirmed using flow cytometry analysis of peripheral blood mononuclear cells.
Wang F., Su H., Xu D., Dai W., Zhang W., Wang Z., Anderson C.F., Zheng M., Oh R., Wan F, & Cui H. (2020). Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel. Nature biomedical engineering, 4(11), 1090-1101.
+ Open protocol
+ Expand
10

T Cell Depletion Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
To deplete T cells, mice were inoculated i.p. with 75 μg of anti-CD8 (clone 2.43, Bio X Cell) or anti-CD4 (clone GK1.5, Bio X Cell) antibodies at day 9, 12, 16 and 21 p.i. Non-depleted control mice were given the same amount of isotype control antibody (clone LTF-2, Bio X Cell).
Misumi I., Mitchell J.E., Lund M.M., Cullen J.M., Lemon S.M, & Whitmire J.K. (2021). T cells protect against hepatitis A virus infection and limit infection-induced liver injury. Journal of hepatology, 75(6), 1323-1334.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!